Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis: A Randomised Double-blind Placebo Controlled Trial
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Apremilast (Primary)
- Indications Hidradenitis suppurativa
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms SMASH
- 01 Feb 2018 Status changed from active, no longer recruiting to completed.
- 19 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.